ImmunityBio, Inc.
ANKTIVA
non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS)
Resolved
208days ago
Advisory committee · Dec 11, 2025
What's at stake
An FDA advisory committee reviews ANKTIVA for non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) around Dec 11, 2025. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on December 11, 2025, which recommended authorization based on its determination that the benefit of making ANKTIVA available to patients—with a complete ”